Inspirna Raises $50 Million in Series D Financing
Funding to further support company in advancing its clinical stage oncology programs NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics, announced that it has raised $50 million in a Series D financing round, co-led by
Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer
Favorable efficacy and safety support further development of RGX-202-01 in advanced or metastatic second-line colorectal cancer NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics, announced today data from the ongoing Phase 1b clinical trial
Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
ORR of 50% and median PFS of 11.8 months in patients with KRAS mutant advanced colorectal cancer (CRC) treated in the second-line Favorable safety profile with a majority of TEAEs Grade 2 or lower, and no DLTs observed Overall efficacy and safety
Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that it will present a poster at the 2022 American Society of Clinical Oncology
Inspirna to Present at 21st Annual Needham Virtual Healthcare Conference
New York, NY – April 7, 2022 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 21st Annual Needham Virtual Healthcare Conference
Inspirna to Participate in Multiple Virtual Healthcare Investor Conferences in March
New York, NY – March 8, 2022 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will participate in multiple virtual healthcare investor conferences taking place
Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology
--Drs. Josep Tabernero, M.D., Ph.D. and Alan Venook, M.D. to Support Company in Advancing Pipeline of Novel Drug Candidates Derived from its RNA-DRIVErTM Discovery Platform NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics,
Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 A.M. EST
Inspirna to Present at the Stifel 2021 Virtual Healthcare Conference
New York, NY – November 10, 2021 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the Stifel 2021 Virtual Healthcare Conference at
Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy® (ipilimumab) for Treatment of Metastatic Endometrial Cancer
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, today announced a collaboration with Bristol Myers Squibb on a clinical trial of a combination therapy using RGX-104 (abequolixron), the Company’s small molecule